Adaptimmune Therapeutics plc (ADAP)
| Previous Close | 1.0600 |
| Open | 1.0600 |
| Bid | 1.0300 x 600 |
| Ask | 1.0500 x 200 |
| Day's Range | 1.0300 - 1.0901 |
| 52 Week Range | 0.4200 - 2.0500 |
| Volume | |
| Avg. Volume | 2,054,151 |
| Market Cap | 268.34M |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | Mar 04, 2024 - Mar 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
ZacksAdaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
NewsfileStrategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchiseUpdate on afami-cel launch plans to be provided at the April 18th Investor DayPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that its strategic collaboration with Genentech entere
NewsfileResults of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and transla
